An observational study in Clear Cell Renal Cell Carcinoma and VHL Syndrome, sponsored by IRCCS San Raffaele. Completed at 1 site in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Carcinoma, Renal Cell with a site in Italy — 28 open to participants now, 47 under way, 15 of them phase 3. Carcinoma, Renal Cell · Italy.
Among the 154 studies in Carcinoma, Renal Cell with a site in Italy, this one is the 30th largest by enrollment of the 30 observational ones that give a count, is one of 9 that started in 2023, is one of 30 observational ones, and was the 132nd registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →28 of the 154 studies in Carcinoma, Renal Cell with a site in Italy are open now. Recruiting first, the newest first:
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 18+
Merck Sharp & Dohme LLC · Sites in Italy, United States, Argentina and 16 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Italy, United States, Argentina and 17 more countries
Ages 18+
Bristol-Myers Squibb · Sites in Italy, United States, Canada and 2 more countries
Ages 18+
Incyte Corporation · Sites in Italy, United States, Australia and 2 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 46 · Phase 3 50 · Phase 4 2
First in 1994; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 153 across 338 observational studies indexed under Carcinoma, Renal Cell.
Median enrollment 252 across the 123 interventional studies, 213 across the 30 observational. Of the 97 that completed or were terminated, 48 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
101 of 154 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
IRCCS San Raffaele has 4 studies filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
12 of the studies in Carcinoma, Renal Cell with a site in Italy that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03815643Phase 3EMD Serono Research & Development Institute, Inc.Avelumab Program Rollover Study | 2026-11-24 |
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT03592472Phase 3Xynomic Pharmaceuticals, Inc.A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | 2026-12-30 |
| NCT03873402Phase 3Bristol-Myers SquibbA Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | 2027-03-11 |
| NCT05789069HiFiBiO TherapeuticsA Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | 2026-12 |
Add all 12 to your calendar (.ics) → With an account.
Among the 154 studies in Carcinoma, Renal Cell with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
It was hypothesized that the high intra- inter-tumor heterogeneity of sporadic ccRCC also defines VHL-ccRCCs, including different lesions within individual patients, and it was assumed that decoding VHL-ccRCC heterogeneity by coupling imaging, histology and molecular profiling of multiregional biopsies would help improve diagnostic tests and therapeutic choices for VHL patients.
In order to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients, the aims of the study are:
This study will develop standardized models for diagnosis and molecular characterization of ccRCC in VHL disease using a combination of imaging, intrasurgical biopsying and multi-omics analysis. It will benefit of a clinical and research program devoted to VHL disease established at OSR in 2021 that centralizes Italian VHL patients. Since the current study relies on tumor biopsy techniques that are already established in clinical practice, the translational findings will be directly available and immediately affecting patients' care.
VHL patients with at least 3 kidney tumors larger that 3cm to be surgically removed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with hereditary Von Hippel-Lindau (VHL) with genetic diagnosis of VHL disease who have at least three tumors larger than 3cm that have to be surgically removed. The procedure involves standard surgery with the additional collection of 15ml of blood.
Other: Blood collection
15ml of blood are harvested before surgery
Integrating Imaging and multiregion biopsy sampling in VHL related ccRCC
Pre-surgery imaging will be integrated using conventional multiparametric MRI with tumor histology of geographical predeterminated multi-region biopsies in each ccRCC of VHL patients.
Time frame: From month 3 to month 20
Determine immune and stromal heterogeneity in VHL-ccRCC
Multiplex immunohistochemistry, bulk and single cell RNA sequencing and somatic mutations analysis with pan-tumor histological assessment will be combined.
Time frame: DNAseq and bulk RNAseq will be carried out from month 7 until month 20. Multiplex immunohistochemistry (IHC) in multiregional biopsies and standard IHC on the whole tumors will be performed the last 12 months of the study.
Generation and characterization of VHL-ccRCC patient-derived organoids
A protocol to generate VHL-ccRCC-derived tumor organoids (patient-derived organoids, PDO) will be optimized to test anti tumor agents like HIF2alpha inhibitor in organoid cultures representative of intra- and inter-tumor heterogeneity.
Time frame: From month 3 until the end of the project.
Ran from Nov 2023 to primary completion in Jun 2025, 19 months.
Of 97 non-industry observational studies under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 241. This study's 19 months is below that.
Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.
Primary completion moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2025, on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.